MedTrace Logo

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

NCT02946684 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2019-07-08

No results posted yet for this study

Summary

This project seeks to determine whether estradiol suppression achieved with adjuvant treatment with an aromatase inhibitor improves end-follicular and midluteal phase parameters during IVF. 128 patients will be randomized to either placebo or active treatment.

Conditions

Interventions

DRUG

Letrozole

Adjuvant therapy to recFSH during ovarian stimulation

DRUG

Placebo

Adjuvant therapy to recFSH during ovarian stimulation

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • Holbaek Sygehus

    collaborator OTHER

  • Region Capital Denmark

    collaborator OTHER

  • Copenhagen University Hospital, Denmark

    collaborator OTHER

  • Zealand University Hospital

    collaborator OTHER

  • Sven O. Skouby

    lead OTHER

Principal Investigators

  • Sven O. Skouby, Professor · Unit of Reproductive Medicine, Herlev/Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-10-30
Completion
2018-10-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946684 on ClinicalTrials.gov